Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.88 |
| ▸ | ACHE | P22303 | 8/20 | 0.61 |
| ▸ | BCHE | P06276 | 6/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7228382 | 0.96 | XDH (0.81) | XDHACHEBCHESIGMAR1 | |
| SCHEMBL1794651 | 0.95 | XDH (0.84) | XDHACHEBCHESIGMAR1 | |
| SCHEMBL7238001 | 0.95 | XDH (0.80) | XDHACHEBCHESIGMAR1MAOA | |
| SCHEMBL7237795 | 0.95 | XDH (0.80) | XDHACHEBCHESIGMAR1MAOA | |
| SCHEMBL7227795 | 0.95 | XDH (0.80) | XDHACHEBCHESIGMAR1MAOA | |
| SCHEMBL1797906 | 0.93 | XDH (0.77) | XDHACHEBCHESIGMAR1 | |
| SCHEMBL13438406 | 0.93 | XDH (0.77) | XDHACHEBCHESIGMAR1MAOB | |
| SCHEMBL1797866 | 0.91 | XDH (0.74) | XDHACHEBCHESIGMAR1MAOA | |
| SCHEMBL1795058 | 0.90 | XDH (0.73) | XDHACHEBCHE | |
| SCHEMBL1793009 | 0.89 | XDH (0.75) | XDHACHEBCHESIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | claimed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | claimed |
| US-6613797-B2 | New xanthone derivatives useful for treating protozoan diseases | INTERLAB, INC. | 2003-09-02 | — | — | US | claimed |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | INTERLAB, INC. | 2002-05-09 | — | — | US | claimed |
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | disclosed |
| US-6613797-B2 | New xanthone derivatives useful for treating protozoan diseases | INTERLAB, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | INTERLAB, INC. | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | XDH 49/4885ACHE 89/4885BCHE 282/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | XDH 49/4885ACHE 43/4885BCHE 175/4885 |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRM1, CHRM3, CHRNA1 | XDH 242/4885ACHE 50/4885BCHE 197/4885 |
| US-20020055644-A1 | Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins | XPA, XDH, HMOX1 | XDH 2/4885ACHE 945/4885BCHE 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.